Attention!

What is the drug PATHTORN®

It is a selective inhibitor of the serine-threonine kinase mTOR (target of mammalian rapamycin), which specifically affects the mTORC1 complex, the signal-converting mTOR kinase, and the regulatory associated protein of mTOR. Everolimus is active due to its high-affinity interaction with the intracellular receptor protein FKBP12.

Dosage form and packaging

Round biconvex tablets, white to white with a yellowish tinge of color.

10 tablets in a contour cell package (blister) made of a combined material based on aluminum foil (PA/Al/PVC) and aluminum foil printed varnished.

Dosage 2.5 mg: 3 contour cell packages (blisters) together with the instructions for use are placed in a pack of cardboard.

Dosages of 5 mg, 10 mg: 3, 6 or 9 contour cell packages (blisters) together with the instructions for use are placed in a pack of cardboard.

Indications for use

- Advanced and / or metastatic renal cell carcinoma with ineffectiveness of antiangiogenic therapy.

- Advanced and / or metastatic neuroendocrine tumors of the gastrointestinal tract (GIT), lung.

- Hormone-dependent advanced breast cancer in postmenopausal patients, in combination with an aromatase inhibitor after previous endocrine therapy.

Efficacy and safety studies

In accordance with current legislation, the drug has proven its effectiveness, safety and quality during state registration. For registration purposes, a bioequivalence study was conducted with the original (reference) medicinal product.